Immunotherapy using immune cells, such as T cells and Natural Killer (NK) cells, is revolutionizing cancer treatment and offering new hope for patients with difficult-to-treat diseases. T cells, a critical component of the adaptive immune system, can be engineered to recognize and attack cancer cells more effectively. One of the most advanced forms of this approach is CAR-T cell therapy, where T cells are modified to express Chimeric Antigen Receptors (CARs) that target specific proteins on the surface of cancer cells. This precise targeting allows CAR-T cells to seek out and destroy cancer cells with high efficacy, making them a powerful tool against hematological malignancies like leukemia and lymphoma.Similarly, Natural Killer (NK) cells, part of the innate immune system, are being harnessed for immunotherapy due to their ability to recognize and kill abnormal cells without prior sensitization. CAR-NK cells are engineered to express CARs, enhancing their ability to target and eliminate cancer cells. Unlike CAR-T cells, CAR-NK cells have a lower risk of causing severe side effects like cytokine release syndrome, making them a promising option for safer immunotherapy treatments.Our manufacturing laboratory is equipped to produce these highly specialized engineered immune cells. We use state-of-the-art techniques to isolate, expand, and genetically modify T cells and NK cells, ensuring they express the necessary receptors to effectively target cancer cells. Our facility adheres to stringent Good Manufacturing Practice (GMP) standards, ensuring that the engineered immune cells are produced with the highest levels of safety, purity, and potency. This capability allows us to provide customized immunotherapy solutions, advancing the fight against cancer and other immune-related diseases with cutting-edge, cell-based therapies.